구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Advanced Hepatocellular Carcinoma (HCC) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel case of clinical and biochemical recovery of ICI-D |
Positioning Known limitation | resistance to cancer immune checkpoint blockade |
MoA Mechanism | targeting the NF-κB/NLRP3/IL-1β pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Half-life | 15.4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity |
Clinical Safety signal | hepatotoxicity |
Clinical Selected reported efficacy | ORR 9% |
Clinical Reported ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT03033576 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03033576 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ipilimumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | Advanced Hepatocellular Carcinoma (HCC) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel case of clinical and biochemical recovery of ICI-D |
Positioning Known limitation | resistance to cancer immune checkpoint blockade |
MoA Mechanism | targeting the NF-κB/NLRP3/IL-1β pathway |
MoA Biomarker | PD-L1) expression |
PK/PD Half-life | 15.4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity |
Clinical Safety signal | hepatotoxicity |
Clinical Selected reported efficacy | ORR 9% |
Clinical Reported ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT03033576 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03033576 |
추천 비교
추천 비교